Congressional Testimony
The reprocessing industry has a long history of stringent legislative and regulatory oversight and examination. Excerpts from statement of Daniel Schultz, M.D., Director, Center for Devices and Radiological Health, Food and Drug Administration (FDA), before the Committee on Government Reform, House of Representatives on September 26, 2006. Dr. Schultz’ full testimony.
Testimony submitted to the Senate Health, Education, Labor and Pensions Committee (HELP) for its hearing on reuse, June 27, 2000:
- FDA’s Written Testimony, presented by David W. Feigal, M.D., Director of the Center for Devices and Radiological Health, Food and Drug & Administration(CDRH) . For more information on the regulation of medical devices see CDRH site
- American Hospital Association’s (AHA) Written Testimony(presented by Dr. John Clough of The Cleveland Clinic)
- U.S. General Accounting Office’s (GAO) Written Testimony and Report Titled “Single-Use Medical Devices: Little Available Evidence of Harm From Reuse, but Oversight Warranted” (PDF file), presented by Dr. Janet Heinrich, Associate Director, Health Financing and Public Health Issues, GAO
Testimony submitted to the House Energy and Commerce Subcommittee on Oversight and Investigations for their hearing on reuse held February 10, 2000:
- FDA’s Written Testimony, presented by David W. Feigal, M.D., Director of the CDRH, FDA
AHA’s Written Testimony, presented by Dr. Walter G. Maurer of The Cleveland Clinic
